Administration of aspirin and rivaroxaban prevents deep vein thrombosis after total knee arthroplasty / 中国组织工程研究
Chinese Journal of Tissue Engineering Research
; (53): 2012-2017, 2014.
Article
in Zh
| WPRIM
| ID: wpr-444085
Responsible library:
WPRO
ABSTRACT
BACKGROUND:
To date, rivaroxaban has been a clinical y common anticoagulant in China;however, effective prophylaxis for venous thrombosis is associated with a markedly higher incidence of perioperative hemorrhagic complications. Although it has been reported that aspirin effectively prevents deep vein thrombosis and pulmonary embolism, the use of aspirin as a routine drug for venous thrombosis after total knee arthroplasty is stil controversial.OBJECTIVE:
To compare the efficacy and safety of aspirin and rivaroxaban for prevention of deep vein thrombosis after total knee arthroplasty.METHODS:
Total y 324 patients with osteoarthritis who underwent primary unilateral total knee arthroplasty were randomly divided into three groups. Twelve hours after the surgery, three groups were given aspirin, rivaroxaban and low-molecular-weight heparin respectively. Al three groups were treated for 14 days, and al of the patients were fol owed for 4 weeks. RESULTS ANDCONCLUSION:
Compared with the low-molecular-weight heparin group, the incidence of deep vein thrombosis was lower (P0.05). The results confirmed that rivaroxaban has a positive anticoagulation effect but leads to increases in wound complications in patients;there are no differences in efficacy and safety between aspirin and low-molecular-weight heparin, so aspirin as part of a multimodal anticoagulation therapy after total knee arthroplasty has good clinical safety and efficacy.
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Tissue Engineering Research
Year:
2014
Document type:
Article
Publication country:
CHINA
/
CN
/
REPUBLIC OF CHINA